Location History:
- Bagsv.ae butted.rd, DK (1999 - 2000)
- Sæborg, DK (2002)
- Søborg, DK (2005)
- Bagsvaerd, DK (1996 - 2007)
- Dyssegård, DK (2013)
- Dyssegaard, DK (2007 - 2022)
- Dyssegaerd, DK (2020 - 2022)
Company Filing History:
22 out of 1,777 
2 out of 1,384 
1 out of 6 
Years Active: 1996-2024
Title: Jens Breinholt: Innovator in Bispecific Antibody Development
Introduction
Jens Breinholt, a prolific inventor based in Bagsvaerd, Denmark, has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With an impressive portfolio of 28 patents, Breinholt has been at the forefront of innovation in therapeutic antibody design.
Latest Patents
Breinholt's latest patents focus on bispecific antibodies that target specific proteins involved in various biological processes. One notable patent describes a bispecific antibody that consists of a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TREM-like transcript 1 (TLT-1). These inventions not only encompass the antibodies themselves but also include pharmaceutical formulations containing these antibodies and their potential uses in therapeutic applications.
Career Highlights
Throughout his career, Jens Breinholt has worked with leading companies in the biotechnology sector, including Novo Nordisk A/S, a global healthcare company specializing in diabetes care and biopharmaceuticals, and Schering Aktiengesellschaft, a pharmaceutical company known for its innovative healthcare solutions. His experiences at these organizations have undoubtedly shaped his expertise and influence in the field.
Collaborations
Breinholt has collaborated with esteemed colleagues such as Ida Hilden and Berit Olsen Krogh. These partnerships have resulted in groundbreaking innovations, reflecting the power of teamwork in advancing scientific research and development.
Conclusion
Jens Breinholt stands out as a key figure in the field of bispecific antibodies, with a noteworthy patent portfolio that highlights his innovative spirit and dedication to biopharmaceutical advancements. Through his work, he continues to impact the landscape of medical treatment and research, paving the way for future discoveries.